tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IFRX Stock Latest News

InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
Company AnnouncementsInflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
4d ago
6K
IFRX
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
PremiumRatings
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
4d ago
IFRX
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%
PremiumThe Fly
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%
4d ago
IFRX
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
PremiumCompany Announcements
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
13d ago
6K
IFRX
InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG
PremiumThe Fly
InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG
13d ago
IFRX
InflaRx announces international nonproprietary name of “izicopan” for INF904
PremiumThe FlyInflaRx announces international nonproprietary name of “izicopan” for INF904
1M ago
IFRX
InflaRx downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
InflaRx downgraded to Market Perform from Outperform at Leerink
1M ago
IFRX
InflaRx downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
InflaRx downgraded to Market Perform from Outperform at Leerink
1M ago
IFRX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
BRR
ETH
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2M ago
HPK
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
PremiumRatings
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
2M ago
IFRX
InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
PremiumThe Fly
InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
2M ago
IFRX
InflaRx price target raised to $9 from $2 at Raymond James
PremiumThe FlyInflaRx price target raised to $9 from $2 at Raymond James
2M ago
IFRX
InflaRx price target raised to $7 from $3 at Oppenheimer
Premium
The Fly
InflaRx price target raised to $7 from $3 at Oppenheimer
2M ago
IFRX
InflaRx price target raised to $24 from $3 at Lucid Capital
Premium
The Fly
InflaRx price target raised to $24 from $3 at Lucid Capital
2M ago
IFRX
Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
PremiumRatings
Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
2M ago
IFRX
InflaRx price target raised to $22 from $10 at Guggenheim
PremiumThe Fly
InflaRx price target raised to $22 from $10 at Guggenheim
2M ago
IFRX
InflaRx reports Phase 2a data for INF904 in HS, CSU
PremiumThe Fly
InflaRx reports Phase 2a data for INF904 in HS, CSU
2M ago
IFRX
InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU
PremiumCompany Announcements
InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU
2M ago
6K
IFRX
InflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges
PremiumCompany AnnouncementsInflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges
2M ago
6K
IFRX
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Premium
Company Announcements
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
3M ago
EDSA
IFRX
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
Premium
Company Announcements
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
3M ago
EDSA
IFRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >